Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases and immune system-related conditions. Its portfolio includes therapies aimed at modulating immune responses to address conditions such as dry eye disease, allergic conjunctivitis, and other inflammatory disorders. The company leverages its proprietary immune modulator platform to explore potential treatments across various therapeutic areas.
Company News
Bragar Eagel & Squire, P.C. is investigating potential claims against Organon, Aldeyra, Landstar, and ICU Medical due to issues related to financial results, regulatory matters, and accounting fraud.
Read about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Aldeyra Therapeutics The Trade: Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million. What’s Happening: On April ...
If you’re looking for penny stocks to invest in right now, you’ve… The post Invest In Penny Stocks? Is It Worth It & 4 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.